Millipore Sigma Vibrant Logo

ABT49 Anti-Dynamin-2 Antibody

Detect Dynamin-2 using this Anti-Dynamin-2 Antibody validated for use in WB.

Anti-Dynamin-2 Antibody: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
Research Category: Cell Structure Research Sub-Category: Cytoskeletal Signaling Gene Symbol: DI-CMTB, DYN2, CMT2M, CMTDI1, CMTDIB, DYNII UniProt Number: P50570
View Products on Sigmaaldrich.com
ABT49
100 µL  
Preis wird abgerufen...
Preis nicht abrufbar
Die Mindestmenge muss ein Vielfaches sein von
Maximum Quantity is
Bei Bestätigung Weitere Informationen
Sie haben () gespart
 
—
Bitte erfragen
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      Sonderaktionen

       

      Kontakt zum Kundenservice

      Übersicht

      Replacement Information

      Sonderaktionen

      100% Performance Guaranteed

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWBRbSerumPolyclonal Antibody
      Description
      Catalogue NumberABT49
      DescriptionAnti-Dynamin-2 Antibody
      Alternate Names
      • dynamin 2
      • dynamin II
      • dynamin-2
      Background InformationDynamin-2 is a ubiquitously expressed, membrane associated protein belonging to the Dynamin protein family of GTPases, a group consisting of three isoforms with distinct tissue specificity and function. Dynamin localizes to plasma membrane-coated pits by its interactions with amphiphysin through the dynamin PRD domain. Dynamin-2 is a component in the manufacture of microtubule bundles, and is capable of both binding and hydrolyzing GTP. It is also likely to be involved in the trafficking mechanisms for vesicles, especially those pertaining to endocytosis. Defects in the expression of Dynamin-2 have been shown to cause Charcot-Marie-Tooth disease dominant intermediate type B (CMTDIB), and centronuclear myopathy autosomal dominant (ADCNM). There is also some interest in Dynamin-2 as a potential regulator for adenovirus targeting cancer therapies.
      References
      Product Information
      FormatSerum
      Control
      • HeLa cell lysate
      PresentationRabbit polyclonal serum containing 0.5% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationDetect Dynamin-2 using this Anti-Dynamin-2 Antibody validated for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenKLH-conjugated linear peptide corresponding to human Dynamin-2.
      HostRabbit
      IsotypeIgG
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryDynamins represent one of the subfamilies of GTP-binding proteins. These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain. Dynamins are associated with microtubules. They have been implicated in cell processes such as endocytosis and cell motility, and in alterations of the membrane that accompany certain activities such as bone resorption by osteoclasts. Dynamins bind many proteins that bind actin and other cytoskeletal proteins. Dynamins can also self-assemble, a process that stimulates GTPase activity. Five alternatively spliced transcripts encoding different proteins have been described. Additional alternatively spliced transcripts may exist, but their full-length nature has not been determined. [provided by RefSeq].
      Gene Symbol
      • DI-CMTB
      • DYN2
      • CMT2M
      • CMTDI1
      • CMTDIB
      • DYNII
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Most probably involved in vesicular trafficking processes, in particular endocytosis.

      CATALYTIC ACTIVITY: GTP + H2O = GDP + phosphate.

      SUBUNIT STRUCTURE: Interacts with MYOF By similarity. Interacts with SHANK1, SHANK2, SH3BP4 and NOSTRIN.

      SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm › cytoskeleton. Cell junction › synapse › postsynaptic cell membrane › postsynaptic density. Cell junction › synapse. Note: Microtubule-associated. Also found in the postsynaptic density of neuronal cells.

      TISSUE SPECIFICTY: Ubiquitously expressed.

      INVOLVEMENT IN DISEASE: Defects in DNM2 are a cause of centronuclear myopathy autosomal dominant (ADCNM) [MIM:160150]; also known as autosomal dominant myotubular myopathy. Centronuclear myopathies (CNMs) are congenital muscle disorders characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. CNMs comprise a wide spectrum of phenotypes, ranging from severe neonatal to mild late-onset familial forms. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.

      Defects in DNM2 are the cause of Charcot-Marie-Tooth disease dominant intermediate type B (CMTDIB) [MIM:606482]. Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. CMTDIB is a form of Charcot-Marie-Tooth disease characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

      MISCELLANEOUS: Overexpression of CNM- and CMT-related DNM2 mutants in COS7 cells, whatever the mutated domain, led to a reduction in clathrin-mediated receptor endocytosis associated with MAPK ERK-1 and ERK-2 impairment. The membrane trafficking impairment process may represent a common pathophysiological pathway in the autosomal forms of CNM DNM2-CMT neuropathy.

      SEQUENCE SIMILARITIES: Belongs to the dynamin family.

      Contains 1 GED domain.

      Contains 1 PH domain.
      Molecular Weight ~ 98 kDa observed
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot in HeLa cell lysate.

      Western Blot Analysis: 1:1,000 dilution of the antibody detected Dynamin-2 in 10 µg of HeLa cell lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt.
      Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      ABT49 04053252290480